We are live on ! Find out more
SM

SG3 Management Portfolio holdings

AUM $6.45K
1-Year Est. Return 61.81%
This Fund
S&P 500
This Quarter Est. Return
+53.66%
1 Year Est. Return
-61.81%
3 Year Est. Return
-38.3%
5 Year Est. Return
-6.2%
10 Year Est. Return
AUM
$1.45B
AUM Growth
+$698M
Cap. Flow
+$418M
Cap. Flow %
28.92%
Top 10 Hldgs %
21.33%
Holding
759
New
418
Increased
75
Reduced
55
Closed
163

Top Sells

Rank Stock Value
1
TSLA icon
Tesla
TSLA
+$16.2M
2
QQQ icon
Invesco QQQ Trust
QQQ
+$4.48M
3
ZM icon
Zoom
ZM
+$3.15M
4
XLF icon
State Street Financial Select Sector SPDR ETF
XLF
+$2.84M
5
LYFT icon
Lyft
LYFT
+$2.67M

Sector Composition

Rank Sector Weight
1 Consumer Discretionary 3.12%
2 Healthcare 2.1%
3 Technology 1.03%
4 Industrials 0.75%
5 Financials 0.71%
Name Market Value Portfolio Weight Shares or Principal Change
in Stake
Capital Flow
KHC icon
126
CALL
Kraft Heinz
KHC
$32.8B
$3.03M 0.21%
95,000
+20,000
+27% +$601K
T icon
127
PUT
AT&T
T
$164B
$3.02M 0.21%
+132,400
New +$3.02M
WES icon
128
PUT
Western Midstream Partners
WES
$19.4B
$3.01M 0.21%
+300,000
New +$2.49M
FND icon
129
CALL
Floor & Decor
FND
$6.03B
$3M 0.21%
52,000
+34,500
+197% +$1.57M
GBT
130
PUT
DELISTED
Global Blood Therapeutics, Inc.
GBT
$2.97M 0.21%
+47,000
New +$3.22M
BMY icon
131
CALL
Bristol-Myers Squibb
BMY
$129B
$2.94M 0.2%
50,000
+27,500
+122% +$1.64M
EBAY icon
132
CALL
eBay
EBAY
$51.2B
$2.93M 0.2%
55,900
-21,900
-28% -$926K
TWOU
133
PUT
DELISTED
2U Inc
TWOU
$2.9M 0.2%
+2,550
New +$2.28M
MRNA icon
134
PUT
Moderna
MRNA
$21.6B
$2.89M 0.2%
45,000
+20,000
+80% +$1.1M
FOLD
135
CALL
DELISTED
Amicus Therapeutics
FOLD
$2.87M 0.2%
+190,000
New +$2.32M
XLRN
136
CALL
DELISTED
Acceleron Pharma
XLRN
$2.86M 0.2%
+30,000
New +$2.89M
XLRN
137
PUT
DELISTED
Acceleron Pharma
XLRN
$2.86M 0.2%
+30,000
New +$2.89M
LITE icon
138
Lumentum
LITE
$46.9B
$2.85M 0.2%
+35,000
New +$2.67M
LSI
139
DELISTED
Life Storage, Inc.
LSI
$2.85M 0.2%
+45,000
New +$2.79M
SPHR icon
140
CALL
Sphere Entertainment
SPHR
$5.02B
$2.81M 0.19%
+37,400
New +$2.87M
CCL icon
141
PUT
Carnival Corporation Ltd
CCL
$38.1B
$2.76M 0.19%
168,000
+118,000
+236% +$1.77M
BYND icon
142
PUT
Beyond Meat
BYND
$274M
$2.75M 0.19%
20,500
-34,500
-63% -$4.08M
PANW icon
143
PUT
Palo Alto Networks
PANW
$256B
$2.73M 0.19%
+71,400
New +$2.52M
EXPE icon
144
Expedia Group
EXPE
$36.5B
$2.67M 0.18%
+32,500
New +$2.36M
AZN icon
145
PUT
AstraZeneca
AZN
$269B
$2.65M 0.18%
+25,000
New +$2.58M
CCI icon
146
CALL
Crown Castle
CCI
$34.6B
$2.64M 0.18%
+15,800
New +$2.54M
BBWI icon
147
CALL
Bath & Body Works
BBWI
$3.97B
$2.62M 0.18%
+216,475
New +$2.41M
TS icon
148
PUT
Tenaris
TS
$28.2B
$2.59M 0.18%
+200,000
New +$2.64M
EDIT icon
149
Editas Medicine
EDIT
$399M
$2.58M 0.18%
87,386
+67,386
+337% +$1.76M
BAX icon
150
CALL
Baxter International
BAX
$12.8B
$2.58M 0.18%
+30,000
New +$2.61M

Similar funds

SG3 Management's Q2 2020 Portfolio in Review

As of Q2 2020, SG3 Management held 759 positions worth $1.45B, up 93% from $748M the previous quarter. Its ten largest holdings account for 21% of the portfolio.

SG3 Management deployed $418M of net new capital in Q2 2020, opening 418 new positions and adding to 75 existing holdings. Its largest new stake was Sea Limited: 183,000 shares worth $19.6M.

By sector, the portfolio is most concentrated in Consumer Discretionary at 3.1% of assets, up from 2% a quarter earlier, followed by Healthcare and Technology.

On the sell side, the largest reduction was Bristol-Myers Squibb, an estimated $1.21M trimmed.

  • SG3 Management's largest Q2 2020 buy was Sea Limited: 183,000 shares worth $19.6M.
  • SG3 Management added most to PENN Entertainment in Q2 2020, an estimated $2.45M increase.
  • SG3 Management's biggest Q2 2020 reduction was Bristol-Myers Squibb, cutting an estimated $1.21M.
  • SG3 Management fully exited Tesla in Q2 2020, selling an estimated $16.2M.
  • SG3 Management's ten largest holdings make up 21% of its $1.45B portfolio in Q2 2020.
  • SG3 Management opened 418 new positions and closed 163 in Q2 2020.
  • SG3 Management's portfolio value rose 93% quarter-over-quarter to $1.45B.

Based on SG3 Management's 13F filing for Q2 2020, filed 14 Aug 2020.